CJC 1295 (no DAC) + Ipamorelin

Description

CJC-1295 (No DAC) + Ipamorelin – research-grade investigational peptide blend

CJC-1295 (No DAC) + Ipamorelin is a dual-peptide research blend associated with two distinct receptor pathways involved in growth-hormone signalling. CJC-1295 without DAC is commonly described as a tetra-substituted growth hormone-releasing factor analogue, or modified GRF(1–29), while ipamorelin is a synthetic pentapeptide growth-hormone secretagogue.

Within laboratory and preclinical research contexts, this combination is of interest because the two components are associated with different upstream signalling mechanisms. The CJC-1295-related component is studied in connection with the growth hormone-releasing hormone receptor pathway, while ipamorelin has been investigated as an agonist of the growth hormone-secretagogue receptor system. This makes the blend relevant for experimental analysis of pituitary signalling, growth-hormone release and associated endocrine-response pathways.

Research relevance of CJC-1295 (No DAC) + Ipamorelin

CJC-1295 (No DAC) + Ipamorelin is commonly associated with:

• Investigation of GHRH receptor-related signalling
• Studies involving growth hormone-secretagogue receptor activity
• Experimental analysis of pituitary growth-hormone release
• Research into growth hormone and IGF-1-related endocrine pathways
• Comparative analysis of individual and combined peptide signalling

Scientific research background

CJC-1295 without DAC is chemically distinct from DAC-modified CJC-1295. The non-DAC form is a synthetic 29-amino-acid GHRH analogue containing substitutions at positions 2, 8, 15 and 27. The attached Drug Affinity Complex used in long-acting CJC-1295 is absent. Published human studies commonly associated with the CJC-1295 name largely examined the long-acting DAC-modified form and should not automatically be applied to non-DAC research material.

Laboratory and animal studies examining ipamorelin have reported growth-hormone release through a GHRP-like receptor pathway. In the original pharmacological study, ipamorelin showed selective growth-hormone-releasing activity in isolated pituitary cells, rats and swine, while producing different ACTH and cortisol responses from certain earlier growth-hormone-releasing peptides.

The combined CJC-1295 and ipamorelin formulation is marketed and has been reported in compounding records, but direct controlled evidence establishing the biological effects, safety or clinical effectiveness of the blend is limited. FDA reviews also note inconsistent naming of CJC-1295-related substances, including uncertainty over DAC status, free-base and salt forms. The exact identity of the CJC-1295 component should therefore be confirmed through appropriate analytical documentation.

Results depend on the exact peptide sequences, molecular forms, component ratio, concentration, experimental model, research conditions, methodology and measured endpoints. Findings concerning either compound individually, particularly DAC-modified CJC-1295, should not be interpreted as confirmed outcomes for the combined non-DAC blend.

FDA has identified potential concerns involving immunogenicity, peptide aggregation, peptide-related impurities and active-ingredient characterisation for both CJC-1295 and ipamorelin. Available human safety information is limited, and the substances are not authorised medicinal products.

Scientific reference

Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139(5):552–561.

FOR RESEARCH USE ONLY

IMPORTANT INFORMATION

• This substance is supplied strictly for laboratory research purposes.
• It is not a food product.
• It is not a dietary supplement.
• It is not an authorised medicinal product.
• It is not intended for human or animal consumption.
• It is not intended for injection, oral administration or nasal administration.
• “No DAC” indicates that the stated CJC-1295 component is intended to exclude the Drug Affinity Complex.
• The product name does not by itself confirm the identity, sequence, DAC status, salt form, component ratio, concentration, purity or sterility of either peptide.
• Findings involving CJC-1295 DAC should not automatically be attributed to CJC-1295 without DAC.
• Keep out of reach of children.
• Keep the container sealed when not in use.
• Store in the original container only.
• Store according to the conditions stated on the product label or certificate of analysis.
• Protect from moisture, excessive heat and direct sunlight.
• Avoid handling during pregnancy or breastfeeding.

In the event of accidental exposure, irritation, illness or any adverse reaction, seek medical advice.